Antibodies, Proteins, Enzymes for drug discovery and molecular diagnostics

Overview:                                                                         LINK to ELISA's

  • ADAMTS
  • HtrAs
  • MMPs
  • Cathepsin
  • Aminopeptidases
  • Cysteinproteinases
  • Zymography Control for drug discovery and
  • Inhibitors for drug discovery and molecular diagnostics
  • Substrates for drug discovery and molecular diagnostics
  • Antibodies for drug discovery and molecular diagnostics
  • Antibodies for mycotoxins, vitamins, hormones and drugs

Details:

Enzymes for drug discovery and molecular diagnostics

MMPs

ADAMTS

HtrAs

Cathepsin

Aminopeptidases

Cysteinproteinases

Kinase

Zymography Control for drug discovery

Inhibitors for drug discovery and molecular diagnostics

Substrates for drug discovery and molecular diagnostics

Antibodies for drug discovery and molecular diagnostics

Antibodies for mycotoxins, vitamins, hormones and drugs

BioTeZ GmbH

Die BioTeZ Berlin-Buch GmbH ist ein Biotechnologie-Unternehmen und wurde 1992 gegründet. BioTeZ ist Partner der Forschung, der Pharmaindustrie und der Labordiagnostik.

  • Biodiagnostika
  • Oligonukleotide
  • Markierte Biomoleküle

Contact

BioTeZ Berlin Buch GmbH
Robert-Rössle-Strasse 10, Haus D 72
13125 Berlin - Germany

Tel: +49 30-9489-2130
Fax: +49 30-9494-509
E-Mail: info@biotez.de
www.biotez.de

Events

MedicaMeet BioTeZ at MEDICA, 12-15 Nov. 2018, Düsseldorf, hall 3, booth G54. 


10th Potsdam Days on Bioanalysis (1./2. November 2018), Potsdam; 
Dr. Janko Brand will give insights in the development projects: recoveryELISA Alirocumab, Evolocumab and PCSK9


SWISS BIOTECH DAY 2018 (3 May 2018, Basel)   Swiss_Biotech_Day
Get Information about diagnostics and biotechnological services we offer: Therapeutic Drug Monitoring, Mycotoxin and Vitamin Analysis, Individual Conjugates, ELISA Development, Oligonucleotides, Human Proteases Research, Streptavidin Coatings, Immobilization Technologies; BioTeZ will summarize outcomes of therapeutic drug monitoring studies with Omalizumab/IgE, Adalimumab/TNF and provide insights into Alirocumab, Evolocumab/PCSK9 recoveryELISA Projects.


Deutsche Biotechnologietage We present at Deutsche Biotechnologietage 18-19 April 2018